Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Adalimumab

Brand: Humira ®
NICE TA: 373
Indication: Juvenile idiopathic arthritis in children and young people (NICE TA373)
Disease category: Musculoskeletal system
Commissioning responsibility: NHS England
PbR excluded: Yes

Background

Adalimumab is recommended as an option for treating polyarticular juvenile idiopathic arthritis (JIA), including polyarticular-onset, polyarticular-course and extended oligoarticular JIA. That is:
- for people 2 years and older whose disease has responded inadequately to 1 or more DMARD.

Adalimumab is recommended as an option for treating enthesitis-related JIA, that is, for people 6 years and older whose disease has responded inadequately to, or who are intolerant of, conventional therapy.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red